- Home
- ZIP vs KPTI Comparison
ZIP vs KPTI Comparison
Compare ZIP & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZIP | KPTI |
|---|---|---|
| Founded | 2010 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 229.6M | 197.3M |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | ZIP | KPTI |
|---|---|---|
| Price | $3.16 | $9.36 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $3.88 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 736.3K | 474.3K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $448,952,000.00 | $146,067,000.00 |
| Revenue This Year | $1.00 | N/A |
| Revenue Next Year | $5.93 | $22.36 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 0.57 |
| 52 Week Low | $1.65 | $3.65 |
| 52 Week High | $6.55 | $10.99 |
Technical Indicators
Market Signals| Indicator | ZIP | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 66.00 | 63.87 |
| Support Level | $1.68 | $5.84 |
| Resistance Level | $4.85 | $9.67 |
| Average True Range (ATR) | 0.20 | 0.60 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 94.48 | 80.39 |
Price Performance
Historical ComparisonAbout ZIP ZipRecruiter Inc.
ZipRecruiter Inc is an online employment marketplace that connects job seekers and employers through an AI-powered platform. The company provides recruiting solutions that help employers identify and hire qualified candidates while enabling job seekers to discover relevant job opportunities through intelligent matching and recommendation tools.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).